Elizabeth A Hahn, Stephanie L Pugh, Hien L Lu, Alyssa M Vela, Erin F Gillespie, Elizabeth M Nichols, Jean L Wright, Shannon M MacDonald, Oren Cahlon, Carole Baas, Lior Z Braunstein, L Christine Fang, Gary M Freedman, Rachel B Jimenez, Christy M Kesslering, Mark V Mishra, Robert W Mutter, Nisha Ohri, Lane R Rosen, James J Urbanic, Reshma Jagsi, Sandra A Mitchell, Justin E Bekelman, David Cella
PURPOSE: Our purpose was to evaluate the measurement properties of patient-reported outcome (PRO) measures used in the ongoing RadComp pragmatic randomized clinical trial (PRCT). METHODS AND MATERIALS: The deidentified and blinded data set included 774 English-speaking female participants who completed their 6-month posttreatment assessment. Eleven PRO measures were evaluated, including the Trial Outcome Index from the Functional Assessment of Cancer Therapy-Breast (FACT-B), Satisfaction with Breast Cosmetic Outcomes, the BREAST-Q, and selected Patient-Reported Outcomes Measurement Information System (PROMIS) measures...
May 13, 2024: International Journal of Radiation Oncology, Biology, Physics